Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates
Samsung Bioepis and Teva Pharmaceutical Industries have entered into an agreement on commercializing the former’s up to six potential biosimilar candidates, including two confirmed investigational candidates, the companies said Thursday. According to Samsung Bioepis, the two sides have signed a global licensing, development and commercialization agreement for the potential candidates. Of them,…
Samsung Bioepis and Teva Pharmaceutical Industries have joined forces to commercialize up to six potential biosimilar candidates, the companies announced on Thursday. The agreement, a global licensing, development, and commercialization deal, covers two confirmed investigational biosimilars: SB41, based on AstraZeneca's Fasenra for severe eosinophilic asthma, and SB44, derived from Novartis' Ilaris for inflammatory conditions like rare autoinflammatory diseases.
Samsung Bioepis will handle development, regulatory registration, and manufacturing, while Teva will focus on global market commercialization, including the U.S., Europe, and Canada. The companies have an option to expand the partnership to additional territories, solidifying Samsung Bioepis' existing relationships.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
